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Mutations of forkhead box p3 (FOXP3), the master gene for naturally occurring regulatory
T cells (nTregs), are responsible for the impaired function of nTregs, resulting in an
autoimmune disease known as the immune dysregulation, polyendocrinopathy, entero-
pathy, X-linked (IPEX) syndrome. The relevance of other peripheral tolerance mechanisms,
such as the presence and function of type 1 regulatory T (Tr1) cells, the major adaptive
IL-10-producing Treg subset, in patients with IPEX syndrome remains to be clarified.
FOXP3mutated Tr1-polarized cells, differentiated in vitro from CD41 T cells of four IPEX
patients, were enriched in IL-101IL-4IFN-c1 T cells, a cytokine production profile specific
for Tr1 cells, and expressed low levels of FOXP3 and high levels of Granzyme-B. IPEX Tr1
cells were hypoproliferative and suppressive, thus indicating that FOXP3mutations did not
impair their function. Furthermore, we isolated Tr1 cell clones from the peripheral blood of
one FOXP3null patient, demonstrating that Tr1 cells are present in vivo and they can be
expanded in vitro in the absence of WT FOXP3. Overall, our results (i) show that functional
Tr1 cells differentiate independently of FOXP3, (ii) confirm that human Tr1 and nTregs are
distinct T-cell lineages, and (iii) suggest that under favorable conditions Tr1 cells could
exert regulatory functions in IPEX patients.
Keywords: Forkhead box p3 . IL-10 . IPEX . Type 1 regulatory T cells
Supporting Information available online
Correspondence: Dr. Rosa Bacchetta
e-mail: rosa.bacchetta@hsr.it
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
DOI 10.1002/eji.201040909 Eur. J. Immunol. 2011. 41: 1120–1131Laura Passerini et al.1120
Introduction
Peripheral T-cell tolerance can be induced and maintained by a
variety of mechanisms, including deletion, induction of T-cell
anergy, and differentiation of Tregs. Among the different subsets
of T cells with suppressive activity so far described, CD41 Tregs are
the most well-defined ones. Naturally occurring CD41CD251
Tregs (nTregs) typically arise in the thymus and their function and
maintenance are dependent on high and stable forkhead box p3
(FOXP3) expression, the master gene regulator of nTreg function
in both mice and humans [1]. We previously demonstrated that
nTregs have varying functional impairment in patients carrying
mutations in FOXP3 [2], who develop a life-threatening auto-
immune disease known as immune dysregulation, polyendocrino-
pathy, enteropathy, X-linked (IPEX) syndrome. This disease is
mainly characterized by enteropathy, diabetes mellitus, thyroiditis,
eczema, and elevated IgE serum levels [3, 4].
In addition to thymus-derived nTregs, adaptive CD41 Tregs
can differentiate in the periphery from naı¨ve precursors under
various tolerogenic conditions. Among these, the type 1 regula-
tory (Tr1) cell subset is typically defined based on the cytokine
production profile (IL-10high, TGF-b1, IL-51, IFN-g1, IL-2low, and
IL-4/low) [5]. Accumulating evidence indicates that Tr1 cells
play a key role in regulating adaptive immune responses in vivo
in both mice and humans, and thus making them potential
candidates for use in cell-based therapies for immune-mediated
diseases [6, 7].
Lineage independence of Tr1 and nTregs has been investi-
gated using murine transgenic models [8]; results from this study
indicate the existence of a FOXP3 IL-10-producing regulatory
cell subset, thus suggesting that in mice Tr1-like cells do not
require FOXP3 for their differentiation and survival. In early
studies, in human healthy subjects, we have demonstrated that
nTregs and Tr1 cells are independent subsets, showing that Tr1
cells can arise in vitro in the absence of CD41CD251 Tregs [9].
Additional studies by us and others have shown that, differently
from nTregs, Tr1 cells do not express constitutive CD25 or
FOXP3, but they can transiently upregulate both markers upon
activation [10–12]. More recently, it has been demonstrated that
a subset of CD41FOXP3 T cells possesses IL-10-dependent
regulatory activity [13]. On the other hand, it has been reported
that CD41CD251 Tregs may also suppress effector T (Teff) cell
responses through the production of IL-10 and TGF-b [14–16]
and that human Tr1 cell clones are converted to Th2 cells upon
knockdown of FOXP3 [17, 18]. Thus based on the available data,
the lineage distinction of these two Treg subsets is still unclear.
Data showing preserved IL-10 production by PBMCs of one IPEX
patient anticipate that FOXP3mut T cells could be the appropriate
model to address this issue [19].
In the present study, we took advantage of the unique
opportunity to study patients with IPEX syndrome (i) to unravel
the developmental and functional relationship between nTregs
and Tr1 cells and (ii) to assess whether Tr1 cells could compen-
sate for nTreg deficiency in IPEX. To these aims, we investigated
both in vitro and in vivo development of Tr1 cells in the absence
of functional FOXP3. Overall, our results show that Tr1 cell
differentiation is independent of FOXP3 and that suppressor
IL-10-producing T cells can arise in vivo in the absence of WT
FOXP3.
Results
FOXP3mutated (mut) naı¨ve CD41 T cells can differentiate
in vitro into Tr1 cells
We activated CD41CD45RO T cells isolated from four IPEX
patients (Pt) (Pt2, 5, 9, and 12, all carrying different FOXP3
mutations) by anti-CD3 cross-linked to CD321 L cells, as artificial
APCs, in the presence of IL-10 and IFN-a, as described previously
[20]. Activation of healthy donor (HD) CD41 naı¨ve T cells under
these culture conditions resulted in the differentiation of a
distinct population of T cells with a Tr1-like cytokine production
profile, as shown by intracellular staining (Fig. 1). In these
culture conditions, a subset of T cells produced IL-10 (% IL-101
T cells: mean7SE: 1171, n510), whereas a markedly lower
proportion of cells produced IL-4 (% IL-41 T cells: mean7SE:
270.4, n510), in comparison to cells cultured in nonpolarizing
conditions (Th0) (% IL-101 T cells: mean7SE: 370.5; % IL-41
T cells: mean7SE: 1172, n5 10) (Fig. 1A and B). Similar to HD
Tr1-polarized T cells, CD41 naı¨ve T cells from IPEX patients
cultured in the presence of IL-10 and IFN-a differentiated in a
population enriched of IL-10-producing T cells (% IL-101 T cells:
mean7SE: 1372, n5 4), with low proportion of IL-4-producing
cells (% IL-41 T cells: mean7SE: 270.5, n5 4), as compared
with control Th0 T-cell cultures (% IL-101 T cells: mean7SE:
772, n5 4; % IL-41 T cells: mean7SE: 1272, n5 4), in which a
higher fraction of cells produced IL-4 (Fig. 1C and D). Both HD-
and patient-derived Tr1-polarized cells contained a substantial
proportion of IFN-g-producing cells (HD % IFN-g1 T cells:
mean7SE: 3673, n510; Pt % IFN-g1 T cells: mean7SE:
40710, n54) part of which also produced IL-10 (HD % IL-101
IFN-g1 T cells: mean7SE: 771, n5 10; Patients % IL-101IFN-g1
T cells: mean7SE: 973, n54) (Fig. 1A and B).
High IL-10 and low IL-4 production by Tr1-polarized cells in
both patients (n5 3) and HDs (IL-10 pg/mL: mean7SE:
26007610; IL-4 pg/mL: mean7SE: 120740, n59) were also
detected in cell-culture supernatants (Fig. 1E). Patients’ and HD’
nonpolarized cells produced variable amounts of IL-10 (HD
IL-10 pg/mL: mean7SE: 271071720, n5 9; Patients: Pt5: 8700,
Pt2: 1830, Pt9: 10 000 pg/mL), but concomitant high IL-4
production was also detected (HD IL-4 pg/mL: mean7SE:
17507640, n59; Patients: Pt5: 1880, Pt2: 1420, Pt9: 1580 pg/
mL), resulting in an overall different cytokine production profile,
with an IL-10/IL-4 ratio lower than in Tr1-polarized cells (HD
IL-10/IL-4 ratio Tr1 versus Th0: 22 versus 2; Patients IL-10/IL-4
ratio Tr1 versus Th0: 36 versus 4).
These results indicate that a T-cell population with a Tr1-like
cytokine production profile can differentiate in vitro from naı¨ve
CD41 T cells carrying mutations in the FOXP3 gene, suggesting
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that FOXP3 is not necessary for in vitro differentiation of Tr1
cells.
Tr1-polarized T cells from both HD and IPEX patients
express low FOXP3 and CD25 and high Granzyme B
To assess whether Tr1-polarized cell cultures were enriched of
FOXP3-expressing cells, FOXP3 expression was detected by
flow cytometric analysis. Similar to nonpolarized culture condi-
tions, differentiation in the presence of IL-10 and IFN-a did
not induce strong upregulation of FOXP3 expression in HD
T cells (Fig. 2A). Only a small fraction of Tr1-polarized T cells
expressed FOXP3, compatibly with repetitive activation and
culture in the presence of IL-2 and IL-15 [21] (%FOXP31 T cells:
range: 9–27, mean7SE: 1972, n5 8). Tr1-polarized T-cell
cultures generated from naı¨ve T cells of Pt5 and Pt9 (who carry
FOXP3 mutations which do not abrogate protein expression, as
reported previously [22, 23]), displayed levels of FOXP3
expression comparable to both autologous nonpolarized controls
and to HD Tr1 cells (Fig. 2A, upper panels and Fig. 2B). In
T-cell cultures derived from naı¨ve T cells of Pt2, FOXP3
expression was not detectable in both Tr1-polarized and control
nonpolarized T cells (Fig. 2A), due to the presence of a FOXP3null
mutation in the T cells of this patient, as confirmed by FOXP3-
sequence analysis of genomic DNA of the polarized cell cultures
(data not shown).
Further phenotypic characterization of Tr1-polarized T-cell
cultures showed reduced CD25 expression, as compared with
nonpolarized controls in both HD and patient-derived cell
Figure 1. Cytokine production profile of FOXP3mut CD41 naı¨ve T cells differentiated under Tr1-polarizing conditions. Cytokine production by
(A, B) Tr1-polarized and (C, D) nonpolarized T cells was determined by intracellular staining after stimulation with immobilized anti-CD3 mAb and
TPA. Dot plots of (A) Tr1-polarized and (C) nonpolarized cells from one representative HD and one patient are shown. Numbers in the plots indicate
the percentage of positive cells in the gate. Gates were set based on isotype controls. The full gating strategy is shown in Supporting Information
Fig. 2A. The graphs summarize the percentage of IL101 (left panels), IL41 (middle panels), and IFN-g1 (right panels) cells detected in (B) Tr1-
polarized and (D) nonpolarized cell cultures from patients (n5 4) and HDs (n5 10). Horizontal line indicates the mean. (E) IL-10 (grey bars) and IL-4
(white bars) released in cell-culture supernatant by Tr1-polarized (left panel) and nonpolarized (right panel) T cells upon anti-CD3 and anti-CD28
mAbs stimulation. Mean7SE of n5 9 HDs is plotted in the graphs. Statistical analysis was performed with the nonparametric Mann–Whitney test
and p-values were 40.05 for all plots.
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cultures (Fig. 2A, middle panels and Fig. 2B). Similar to HD Tr1-
polarized cells, FOXP3mut Tr1 cells expressed higher levels of
Granzyme B than their nonpolarized counterparts (Fig. 2A, lower
panels and Fig. 2B), whereas the expression of Granzyme A was
similar in all culture conditions (data not shown). Therefore,
Granzyme B expression, which characterizes Tr1 cells [24, 25]
and is typically induced by IL-10 [26], appears to be independent
of FOXP3 since both HD and patients’ Tr1-cell populations
upregulate this marker.
Expressions of the cell-surface molecules IL-15R, CD122
(IL-2Rb chain), and CD132 (IL-2Rg chain), previously reported
to be upregulated on Tr1 cells [27], and of the intracyto-
plasmic Treg-associated marker cytotoxic T-lymphocyte
antigen 4 (CTLA-4) were also tested, but no difference
between Tr1-polarizing and nonpolarizing conditions was
detected, most likely due to the prolonged culture in the
presence of IL-2 and IL-15 (data not shown). Overall, the
phenotypic analysis of FOXP3mut Tr1-polarized cells confirms that
FOXP3 is expressed at low levels in Tr1 cells and demonstrates
that FOXP3mut Tr1 cells are phenotypically similar to their WT
counterpart.
FOXP3mut Tr1-polarized T cells display in vitro
suppressive activity
In addition to their cytokine production profile, Tr1 cells are
functionally characterized by their intrinsic low proliferative
capacity and in vitro suppressive function [10, 27, 28].
Similar to HD, in comparison to nonpolarized control
cultures, FOXP3mut Tr1-polarized T cells displayed a reduced
proliferative response to TCR-mediated activation in the presence
or absence of costimulation (Fig. 3A and B) (% reduction of
proliferation of HD IL-101IFN-a polarized versus nonpolarized
T cells: anti-CD3 mAb stimulation range: 20–88%; mean7SE:
64710%; anti-CD31anti-CD28 mAbs stimulation range:
25–90%, mean7SE: 58711%; n56).
To establish the functional capacity of in vitro-differentiated
FOXP3mut Tr1 cells to act as suppressor cells, we tested whether
naı¨ve T cells from IPEX patients differentiated in Tr1-polarizing
conditions could suppress the proliferation of allogeneic CD41
T cells as efficiently as HD Tr1 cells. As shown in Fig. 3C, addition
of control Th0 cells, primed in the absence of polarizing
cytokines, had minimal effect on the proliferation of allogeneic
Figure 2. Phenotypic characterization of FOXP3mut CD41 naı¨ve T cells differentiated in Tr1-polarizing conditions. (A) Cell-surface CD25 (middle
panels) and intracellular FOXP3 (upper panels) and Granzyme B (lower panels) expression in nonpolarized (thin line) or Tr1-polarized (thick line)
cells differentiated from naı¨ve CD41 T cells of patients and one representative HD are shown. Numbers in the plots indicate the percentage and
MFI of positive cells. The full gating strategy is shown in Supporting Information Fig. 2B. (B) The graphs summarize the data obtained from T cells
of HDs (white symbols) and patients (black symbols) differentiated in Tr1-polarized (circles) or nonpolarizing (triangles) conditions at the end of 2-
wk culture without further reactivation. Horizontal lines indicate the mean. Statistical analysis was performed with the nonparametric
Mann–Whitney test. NS, not significant.
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CD41 T cells. On the contrary, T cells cultured in the presence of
IL-10 and IFN-a strongly suppressed the proliferation of respon-
der T cells. The percentage of inhibition of Tr1-polarized cells
from IPEX patients was comparable to that observed in Tr1 cells
differentiated from normal donors (at [responder:suppressor]
ratio of [1:1], range: 45–91%; mean7SE: 6977%; n5 6) and to
the suppressive capacity of CD251 Tregs freshly isolated from
HDs and tested under the same culture conditions (range:
43–74%; mean7SE: 5977%; n54) (Fig. 3C and D). The
observation that CD41 T cells differentiated with IL-10 and IFN-a
display a hypoproliferative response to TCR stimulation inde-
pendently of FOXP3 expression suggests that their anergic
phenotype, as their suppressive activity, is not dependent on
FOXP3.
Functional Tr1-cell clones can be isolated from the
peripheral blood of patients with IPEX syndrome
To determine whether Tr1 cells could arise in vivo in IPEX
patients, T-cell clones were randomly generated starting from
peripheral CD41 T cells of a patient carrying a FOXP3null
mutation (Pt2, mutation: 3G>A [22, 29]). Pt2 received bone
marrow transplant (BMT), but donor chimerism decreased
rapidly after transplant, remained persistently low, and in the
CD41 T-cell compartment was below 10% at the time of T-cell
cloning [29].
We selected T-cell clones that upon activation produced IL-10,
with concomitant low IL-4, as potential Tr1-cell clones for further
characterization of cytokine production, DNA sequence analysis
for host/donor origin identification and functional properties.
The presence of FOXP3null T-cell clones with a Tr1-like
cytokine production profile was confirmed by the analysis of
cytokines in supernatants of activated T cells. In this analysis, we
classified a T-cell clone as Tr1 when the IL-10/IL-4 ratio was at
least 30-fold (high IL-10/IL-4 ratio is a hallmark of Tr1-cell
clones [30]), with concomitant negative or low IL-2 production.
T-cell clones with IL-10/IL-4 ratio over 100 were classified as
Tr1-cell clones independently of IL-2 production. The majority
of T-cell clones analyzed, either Tr1- or Th-cell clones, were of
host origin (Fig. 4A and B), in accordance with low donor
chimerism in peripheral blood.
Overall, 60% of the T-cell clones with a Tr1-like cytokine
production profile were of host origin (Fig. 4A and Supporting
Information Tables 1 and 2) and the amount of cytokines
produced was comparable to Tr1-cell clones of donor origin
(Fig. 4A), suggesting that the presence of a FOXP3null mutation
does not hamper in vivo differentiation of Tr1 cells. The complete
absence of FOXP3 protein translation was confirmed by FACS
analysis of activated T-cell clones of donor and host origin
carrying the FOXP3null mutation (Fig. 4C).
Similar to HD Tr1-cell clones [10, 28], FOXP3mut Tr1-cell
clones displayed reduced proliferative capacity in response to
TCR-mediated activation, as compared with Th-cell clones of host
Figure 3. Functional characterization of FOXP3mut CD41 naı¨ve T cells differentiated in Tr1-polarizing conditions. (A) Tr1-polarized (white bars) and
nonpolarized (grey bars) cells were stimulated with immobilized anti-CD3 mAb alone (left panel) or plus anti-CD28 mAb (right panel). Numbers in
the plots indicate the percent anergy calculated versus nonpolarized controls. (B) The graph summarizes the percent anergy calculated versus
nonpolarized controls of all HDs (n5 6) and patients (n5 3) tested. Horizontal lines indicate the mean. Statistical analysis was performed with the
nonparametric Mann–Whitney test, p-value was 40.05 for both groups. (C) The capacity of Tr1-polarized cells differentiated from naı¨ve T cells of
patients to suppress the proliferation of allogeneic CD41 T cells was evaluated by CFSE dilution assay. Numbers in the plots indicate the
percentage inhibition of proliferation. n.t., not tested; R, responder T cells. The full gating strategy is shown in Supporting Information Fig. 3.
(D) The graph summarizes the percentage inhibition of proliferation by Tr1-polarized cells from the three patients tested in (C) (black circles) and a
pool of HDs (white circles). As a control, the percentage suppression of CD251 Tregs freshly isolated from the peripheral blood of HDs (white
triangles) is also shown. Horizontal lines indicate the mean. Differences in the suppressive capacity of patients’ Tr1-polarized cells versus that of
HDs’ Tr1 cells was evaluated with Mann–Whitney test, p-value was 40.05. NS, not significant.
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origin, used as control (mean % reduction: 46 versus FOXP3mut
Th-cell clones; Tr1 n5 5; Th n57) (data not shown). Moreover,
FOXP3mut Tr1-cell clones were able to suppress the proliferative
response of allogeneic CD41 T cells as efficiently as FOXP3WT Tr1-
cell clones, tested in parallel (Fig. 4D). T-cell clones of host origin
displaying a low IL-10/IL-4 ratio were used as control Th-cell
clones (Fig. 4D). Among the T-cell clones with a Tr1-like cytokine
production profile tested for in vitro suppression, two out of three
T-cell clones expressing WT FOXP3 significantly reduced the
proliferation of allogeneic CD41 T cells (>30% suppression at
[CD41responders:suppressors] ratio of [1:1]). Similar to
FOXP3WT Tr1-cell clones, two out of five of the FOXP3mut Tr1-like
cell clones tested (n5 5) displayed efficient in vitro suppressive
activity (Supporting Information Table 3). Furthermore, block-
Figure 4. Characterization of ex vivo-isolated FOXP3null T-cell clones. Cytokine production profile of Tr1 (A) and Th (B)-cell clones of host (grey bars)
and donor (white bars) origin was determined upon anti-CD3 plus anti-CD28 mAbs stimulation. Results are presented as mean7SE. Statistical
analysis was performed with the two-tailed unpaired Student’s t-test, p>0.05 for all cytokines. NS: not significant. (C) T-cell clones of host (left
panels) and donor (right panels) origin were activated for 48 hours in the presence of anti-CD3/anti-CD28 mAbs and IL-2 (100 U/mL) prior to FOXP3
staining. Representative T-cell clones of host and donor origin are shown. Numbers in the plots indicate the percentage of positive cells in the
quadrant. T cells were gated on Live cell gate, and identified based on the physical parameters, as shown. (D) The ability of FOXP3null (grey bars)
Tr1-cell clones to suppress CD41 allogeneic responder (R) T cells was assessed by CFSE dilution assay. The full FACS gating strategy is shown in
Supporting Information Fig. 3. FOXP3WT (white bars) Tr1-cell clones of donor origin were tested in parallel. As control, both FOXP3null and FOXP3WT
Th-cell clones were also tested. Numbers in the plots indicate the percentage inhibition of proliferation. Data are representative of two
independent experiments.
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ade of IL-10 and TGF-b, by adding to the co-culture anti-IL-10R
and anti-TGF-b mAbs, partially reverted the suppressive activity
of both FOXP3WT and FOXP3null Tr1-like cell clones (% reversion
of suppressive activity range was 16–41% for FOXP3WT Tr1-cell
clones, n5 3 and 13–100% for FOXP3mut Tr1-cell clones, n52)
(Supporting Information Fig. 1). In addition, the suppressive
activity of a FOXP31 Treg clone generated from FACS sorted
CD41CD25bright T cells of a HD, used as control, was not reverted
in the presence of anti-IL-10R and anti-TGF-b mAbs (Supporting
Information Fig. 1).
Overall, these results demonstrate that both FOXP3null and
FOXP3WT Tr1-cell clones showed similar in vitro functional
properties and that suppressive activity of the FOXP3null Tr1 cells
is indeed IL-10- and TGF-b-dependent, as previously demon-
strated for WT Tr1 cells [11, 31].
We further investigated the presence of circulating
IL-10-producing cells in the peripheral blood of patients with
IPEX syndrome by evaluation of IL-10 production by patients’
PBMCs upon TCR-mediated stimulation. As shown in Fig. 5, low
IL-10 production was detected in long-term IPEX patients, young
adults who overcame the initial acute phase of the disease and
were under treatment with immunosuppressive drugs (Table 1).
Low IL-10 release by peripheral T cells was also detected in a
group of non-IPEX patients, without detectable FOXP3 mutation,
but with autoimmune manifestations of unknown origin (most of
them displayed enteritis) kept under control by multiple immu-
nosuppressive treatments (Fig. 5). These patients served as
control group to assess the impact of IS on in vitro IL-10
production upon TCR-mediated stimulation. However, pheno-
typic analysis of patients’ CD41CD25CD127 T cells, a T-cell
population recently described to include a fraction of memory
IL-10-producing cells with regulatory activity [13], revealed
frequencies similar to healthy controls (data not shown). Overall,
these data suggest that, although present and normally differ-
entiating, Tr1 cells in IPEX patients are not as efficient as those in
healthy control.
Discussion
In the present study, we show that suppressor Tr1 cells can
differentiate in vitro from naı¨ve CD41 T cells isolated from IPEX
patients, carrying different mutations in the FOXP3 gene.
Furthermore, we demonstrate that Tr1-cell clones are present
in the peripheral blood of a patient carrying a FOXP3null
mutation. These results indicate that FOXP3 is not required for
both in vitro and in vivo differentiation of Tr1 cells. Tr1 cells
obtained in vitro or isolated ex vivo from IPEX patients display all
the features commonly adopted to define Tr1 cells [5]. In vitro-
differentiated FOXP3mut Tr1 cells are hypoproliferative, produce
high levels of IL-10, with concomitant low IL-4 and IL-2, express
high levels of Granzyme B and low CD25 and, most importantly,
display in vitro suppressive activity. The above-mentioned
properties are also shared by FOXP3mut Tr1-cell clones induced
in vivo. Nonetheless, clinical evidence demonstrates that the lack
of nTregs in infants with IPEX syndrome is not fully compensated
by the induction of functional Tr1 cells.
Similar to FOXP3WT Tr1 cells, FOXP3mut Tr1 cells or Tr1-cell
clones consistently show high IL-10 production and in vitro
suppressive capacity. Furthermore, FOXP3mut cells induced in
vitro [11, 12] or isolated ex vivo show low FOXP3 expression,
whose intensity may vary based on the state of activation of the
cells at the time of analysis, as reported previously. These findings
support the notion that FOXP3 is not important for the main-
tenance of Tr1-cell features and function [11, 12]. Indeed, IL-10-
producing T cells have been previously obtained from one IPEX
patient after short-term in vitro stimulation [19]. Our results not
only extend these findings to patients with different FOXP3
mutations, thus demonstrating that Tr1-cell fate is independent
from FOXP3, but also provide evidence that FOXP3mut Tr1 cells
can differentiate in vivo and display features and function similar
to FOXP3WT Tr1 cells.
Although lineage relationship between Tr1 cells and nTregs
has not been fully unraveled, using transgenic mice with a dual-
reporter system of the genes encoding IL-10 and Foxp3, it has
been previously demonstrated that three distinct Treg subsets
exist: Foxp31IL-101, Foxp31IL-10, and Foxp3IL-101 (defined
as Tr1-like) Tregs and their relative frequency varies depending
on the tissue compartment [8]. These results indicate that in the
mouse, induction of IL-10 expression is initiated extrathymically
regardless of Foxp3 expression [8]. Similarly, human Tr1-cell
differentiation in vitro does not require CD41CD251 Tregs [11].
Here, we provide definitive evidence that the expression of
FOXP3 is not necessary for Tr1-cell differentiation or function,
thus indicating that nTregs and Tr1 cells in humans are two
distinct subsets of cells with regulatory activity.
Importantly, the isolation of T-cell clones with a Tr1-like
cytokine production profile from the peripheral blood of a
transplanted patient with a FOXP3null mutation indicates that
functional Tr1 cells can arise in vivo regardless of FOXP3
expression. In apparent contrast to these evidences, it has been
Figure 5. IL-10 production by PBMCs isolated from patients with IPEX
syndrome. PBMCs were activated with anti-CD3/CD28 mAbs for 72 h.
n5 7 independent determinations of n5 4 long-term patients (Pt9, 11,
14, and 20, all under immunosuppressive treatment since at least 4
years) (black circles), of n5 5 non-IPEX patients (black triangles),
treated with multiple immunosuppressive drugs, and of n5 21 adult
HDs (white circles) are shown. Horizontal lines indicate the mean.
Statistical analysis was performed with the nonparametric
Mann–Whitney test. po0.05.
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recently reported by Veldman et al. that human Tr1-cell clones
specific for desmoglein3 (Dsg3) constitutively express FOXP3 and
knockdown of FOXP3 expression results in loss of Tr1 phenotype
and function [17, 18]. Notably, in their studies, FOXP3 expres-
sion in Tr1-cell clones was measured exclusively by qPCR analysis
[17, 18]. Tr1 cells, as well as peripheral CD41CD251 T cells,
displayed only a four-fold increase in FOXP3 expression as
compared with purified CD41CD25 Teff cells, corresponding to
a low level of FOXP3 expression, comparable to that of activated
Teff cells, as already reported by us and others [11, 32, 33]. In
addition, the observed lack of suppressive activity by Tr1 cell
clones upon FOXP3 knockdown may be due to subsequent
reversion of the hypoproliferative state of T cells, as already
demonstrated for nTregs [34], rather than to a specific function
for FOXP3 in the suppressor activity of Tr1 cells [18].
Overall, it is relevant that we isolated Tr1 cells carrying a
FOXP3null mutation several years after transplant, in the absence
of immunosuppression, in a chimeric environment. Indeed, in
other mixed chimeric patients, who underwent HSCT for diseases
other than IPEX, Tr1 cells are key players in the maintenance of
persistent mixed chimerism [27, 30]. In this patient, nTregs are
entirely donor-derived, and therefore fully FOXP3WT [29],
whereas Tr1 cells are of both host (FOXP3null) and donor
(FOXP3WT) origin and it is likely that they are operational in vivo
in maintaining tolerance. Although based on the number of T-cell
clones obtained upon in vitro culture we cannot evaluate the
peripheral frequency of Tr1 cells of host and donor origin, our
data suggest that in vivo FOXP3WT Tr1 cells, differently from
nTregs, do not display preferential growth, as compared with
their FOXP3null counterpart.
However, in IPEX patients, the rapid development of the
wasting autoimmune disease after birth indicates that, although
inducible, Tr1 cells are not sufficient by themselves to control
autoimmunity, especially not at the onset of the disease. We
could speculate that the strong inflammatory environment that
characterizes IPEX syndrome at the onset [35, 36] interferes with
Tr1-cell induction, which requires persistent antigen exposure in
tolerogenic environmental conditions [37, 38]. Alternatively, it
cannot be excluded that WT FOXP3 expression in T cells is
required for interaction with APCs in order to induce a tolero-
genic environment suitable for Tr1-cell induction in vivo.
In addition, in those patients who have overcome the initial
acute phase and have become stable with a milder form of the
disease controlled by pharmacological immunosuppression, we
observed low IL-10-production. This suggests that at this stage of
the disease Tr1-cell function may be prevented by the presence of
immunosuppressants. Therefore, therapeutic strategies aimed at
dampening inflammation without interfering with the develop-
ment and function of Tr1 cells [39] should be preferred to strong
immunosuppression. The beneficial effect of rapamycin, reported
in several IPEX patients [40, 41], could potentially be ascribed to
a similar phenomenon.
In conclusion, our results demonstrate that despite mutations
in FOXP3, fully functional IL-10-producing Tr1 cells can differ-
entiate, but it remains to be defined to which extent the devel-
opment of a functional Tr1-cell pool in vivo would allow the
control of the acute phase and the progression toward a milder
form of the disease. Further investigation is needed to address
this issue and define the suitable environmental conditions
favoring the development of an efficient Tr1-cell population, not
only in IPEX syndrome but also in other pathologies with immune
dysregulation.
Materials and methods
Patients and cell purification
The clinical and molecular details of the patients (pt) included in
the study are summarized in Table 1. Peripheral blood was
obtained upon informed consent in accordance with the internal
ethical committee of San Raffaele Scientific Institute approval
(protocol TIGET-02). Pt12 was studied at the onset of the disease,
whereas samples from Pt2, 5, 9, 11, 14, and 20 were obtained
several years after onset. Pt2 underwent bone marrow transplant;
his cells were studied 4 years after transplant when the donor
chimerism was stably below 10% in CD41 T-cell compartment [29].
Pt9, 11, 14, and 20 were under immunosuppression at the time of
this study. All patients except Pt20 were reported previously [22]
(Table 1). In Fig. 5, control patients are subjects with multiple
autoimmune manifestations (which include enteropathy, endocri-
nopathies, and skin diseases) (n55) who were investigated for the
presence of mutations in FOXP3, but were found to be negative. All
patients were under immunosuppressive treatment at the time of
determination. PBMCs were purified over Ficoll-Hypaque gradients.
CD41 and CD45RO T cells were isolated by negative selection
(Miltenyi Biotec) and were over 90% pure.
T-cell culture
In vitro Tr1-cell differentiation was performed in the presence of
IL-10 and IFN-a, as described previously [20]. As a control, T cells
were cultured in the absence of polarizing cytokines (hereafter,
indicated as nonpolarized or Th0 cultures). Prior to suppression
assays, the IL-10-producing fraction of Tr1-polarized cells was
enriched with the IL-10-producing-cell isolation kit (Miltenyi
Biotec), following the manufacturer’s instructions. T-cell clones
were obtained from CD41 cells by limiting dilution, as described
previously [27] and were expanded with IL-2 40U/mL and IL-15
10 ng/mL (R&D Systems). All cultures were performed in
X-Vivo15 (Bio-whittaker), 5% human serum (Bio-whittaker) plus
penicillin/streptomycin (Invitrogen).
T-cell proliferation and suppression assays
In order to evaluate the proliferative response of cultured T cells,
0.5–1 105 cells/well were activated with plate-bound anti-CD3
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mAb 1–10 mg/mL (OKT3; Janssen-Cilag), alone or plus soluble
anti-CD28 mAb 1mg/mL (BD Pharmingen). After 72 h, cells were
pulsed for 16 h with 1 mCi/well of [3H]-thymidine (Amersham
Biosciences). To evaluate the suppressive activity, allogeneic
CD41 T cells were stained with CFSE (Molecular Probes)
and activated with plate-bound anti-CD3 10mg/mL (Janssen-
Cilag) plus soluble anti-CD28 1mg/mL mAbs (BD Pharmingen)
(assay on Pt5, Fig. 2C, panel 1) or with irradiated allogeneic
APC plus anti-CD3 mAb 1mg/mL (Janssen-Cilag) (assays
on Pt2, 9; Fig. 2C, panels 2–3). Suppressor cells were added at
a ratio of 1:1. To evaluate the suppressive activity of Tr1-cell
clones, allogeneic PBMCs were used as responders (R) and
activated with plate-bound anti-CD3 10 mg/mL (Janssen-Cilag)
and soluble anti-CD28 1mg/mL mAbs (BD Pharmingen). T-cell
clones were added either at a ratio of 1:1 or at a ratio of 1:0.5
(CD41 T cell:T-cell clone). To revert the suppressive capacity of
Tr1-cell clones, anti-IL-10RB (clone 3F9) 30 mg/mL (BD Pharmin-
gen) and anti-TGF-b(1,2,3) (clone 1D11) 50 mg/mL (R&D
Systems) mAbs were added to the coculture. As a negative
control, isotype IgGs were added. The percentage of divided
R was calculated by gating on CD41 cells, as described elsewhere
[42]. Tr1 cells inhibiting responder cell proliferation less than
30% at [1:1] and 15% at [1:0.5] [R:Tr] ratio were not considered
suppressive.
Cytokine production
A total of 106 T cells/mL were activated with anti-CD3 10 mg/mL
(Janssen-Cilag) plus soluble anti-CD28 1mg/mL mAbs (BD
Pharmingen). Supernatants were collected after 24 h for IL-2
detection and 48h for all other cytokines. The presence of
cytokines in culture supernatants from T-cell clones was
evaluated by ELISA as described elsewhere [43]. IL-10 produc-
tion by patients’ PBMC was evaluated in cell-culture supernatants
after 72h of activation and analyzed with flow-based Bio-Plex
suspension array system (Biorad).
FACS analysis
Anti-CD4, -CD25, and -CD45RO were all from BD Pharmingen.
Intracellular staining was used for the detection of Granzyme B
(Caltag) and FOXP3 (clone 259D, Biolegend), following the
manufacturers’ instructions. Intracellular cytokines were detected
by flow cytometry using anti-IL-10, IL-4, and IFN-g mAbs (all
from BD Pharmingen), as described by Sornasse et al. [44].
Samples were analyzed with FCS Express Pro Software version 3
(De Novo Software).
Statistical analysis
Results are presented as mean7SE or SD, as indicated in the text,
and analyzed with nonparametric Mann–Whitney test or with
two-tailed unpaired Student’s t-test, as indicated in the figure
legends. Po0.05 was considered significant.
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